Loading...

Silk Road Medical

Nasdaq:SILK
Snowflake Description

Limited growth with worrying balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SILK
Nasdaq
$1B
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

Silk Road Medical, Inc. operates as a medical device company in the United States. The last earnings update was 7 days ago. More info.


Add to Portfolio Compare Print
  • Silk Road Medical has significant price volatility in the past 3 months.
SILK Share Price and Events
7 Day Returns
1.1%
NasdaqGM:SILK
1.1%
US Medical Equipment
1.6%
US Market
1 Year Returns
-
NasdaqGM:SILK
10%
US Medical Equipment
2.6%
US Market
SILK Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Silk Road Medical (SILK) 1.1% 38.6% - - - -
US Medical Equipment 1.1% 3% -0.9% 10% 57.5% 91.3%
US Market 1.6% -1.7% 2.1% 2.6% 38.5% 41.4%
1 Year Return vs Industry and Market
  • No trading data on SILK.
  • No trading data on SILK.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is Silk Road Medical undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Silk Road Medical is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Silk Road Medical has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Silk Road Medical. This is due to cash flow or dividend data being unavailable. The share price is $48.51.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Silk Road Medical's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Silk Road Medical's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:SILK PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-20.81
NasdaqGM:SILK Share Price ** NasdaqGM (2019-05-21) in USD $48.51
United States of America Medical Equipment Industry PE Ratio Median Figure of 64 Publicly-Listed Medical Equipment Companies 38.79x
United States of America Market PE Ratio Median Figure of 3,087 Publicly-Listed Companies 17.74x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Silk Road Medical.

NasdaqGM:SILK PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:SILK Share Price ÷ EPS (both in USD)

= 48.51 ÷ -20.81

-2.33x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Silk Road Medical is loss making, we can't compare its value to the US Medical Equipment industry average.
  • Silk Road Medical is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Silk Road Medical's expected growth come at a high price?
Raw Data
NasdaqGM:SILK PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.33x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
61%per year
United States of America Medical Equipment Industry PEG Ratio Median Figure of 55 Publicly-Listed Medical Equipment Companies 2.21x
United States of America Market PEG Ratio Median Figure of 2,123 Publicly-Listed Companies 1.53x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Silk Road Medical, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Silk Road Medical's assets?
Raw Data
NasdaqGM:SILK PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $-114.00
NasdaqGM:SILK Share Price * NasdaqGM (2019-05-21) in USD $48.51
United States of America Medical Equipment Industry PB Ratio Median Figure of 184 Publicly-Listed Medical Equipment Companies 4.52x
United States of America Market PB Ratio Median Figure of 5,202 Publicly-Listed Companies 1.84x
NasdaqGM:SILK PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:SILK Share Price ÷ Book Value per Share (both in USD)

= 48.51 ÷ -114.00

-0.43x

* Primary Listing of Silk Road Medical.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Silk Road Medical has negative assets, we can't compare the value of its assets to the US Medical Equipment industry average.

Next steps:

  1. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Silk Road Medical's regulatory filings and announcements.
  2. Show me more potentially undervalued companies in the Medical Equipment industry
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Silk Road Medical's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Silk Road Medical has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Silk Road Medical expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
61%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Silk Road Medical expected to grow at an attractive rate?
  • Unable to compare Silk Road Medical's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Silk Road Medical's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Silk Road Medical's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:SILK Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:SILK Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 61%
NasdaqGM:SILK Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 30.1%
United States of America Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 21.5%
United States of America Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 8.2%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.8%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:SILK Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:SILK Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 199 2
2022-12-31 163 1
2021-12-31 123 -3 -5 3
2020-12-31 90 -18 -25 4
2019-12-31 60 -44 -49 4
NasdaqGM:SILK Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 42 -26 -56
2018-12-31 35 -22 -38
2017-12-31 14 -25 -19

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Silk Road Medical is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Silk Road Medical's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:SILK Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Silk Road Medical Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:SILK Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 -0.16 -0.11 -0.21 3.00
2020-12-31 -0.78 -0.72 -0.89 4.00
2019-12-31 -1.65 -1.43 -2.07 3.00
NasdaqGM:SILK Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -20.81
2018-12-31 -14.50
2017-12-31 -16.51

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Silk Road Medical will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Silk Road Medical's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Silk Road Medical has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Silk Road Medical performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Silk Road Medical's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Silk Road Medical does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Silk Road Medical's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Silk Road Medical's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Silk Road Medical's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Silk Road Medical Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:SILK Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 41.62 -56.38 42.37 10.87
2018-12-31 34.56 -37.63 34.82 10.26
2017-12-31 14.26 -19.36 20.26 7.24

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Silk Road Medical has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Silk Road Medical has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Silk Road Medical improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Silk Road Medical's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Silk Road Medical has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Silk Road Medical's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Silk Road Medical's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Silk Road Medical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Silk Road Medical's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Silk Road Medical's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Silk Road Medical has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Silk Road Medical Company Filings, last reported 1 month ago.

NasdaqGM:SILK Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 -21.01 49.59 15.51
2018-12-31 -13.23 44.20 24.99
2017-12-31 10.84 27.59 33.33
  • Silk Road Medical has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Silk Road Medical's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Silk Road Medical has less than a year of cash runway based on current free cash flow.
  • Silk Road Medical has less than a year of cash runway if free cash flow continues to grow at historical rates of 2.3% each year.
X
Financial health checks
We assess Silk Road Medical's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Silk Road Medical has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Silk Road Medical's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Silk Road Medical dividends. Estimated to be 0% next year.
If you bought $2,000 of Silk Road Medical shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Silk Road Medical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Silk Road Medical's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:SILK Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
United States of America Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 24 Stocks 1.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2003 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:SILK Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Silk Road Medical has not reported any payouts.
  • Unable to verify if Silk Road Medical's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Silk Road Medical's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Silk Road Medical has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Silk Road Medical's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Silk Road Medical's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Silk Road Medical afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Silk Road Medical has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Silk Road Medical's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Erica Rogers
AGE 54
TENURE AS CEO 6.6 years
CEO Bio

Ms. Erica J. Rogers serves as the Chief Executive Officer and President of Silk Road Medical Inc since October 2012. Ms. Rogers served as Chief Operating Officer of Medicines360 from June 2010 to October 2012. Ms. Rogers founded and was Chief Executive Officer of Allux Medical, and co-founded Visiogen, which was acquired by Abbott Medical Optics in 2009. Ms. Rogers was an Executive Vice President at Nanosys, Inc. from December 2008 to March 2010. She served as the President and Chief Executive Officer of a privately held medical device company, founder of two venture backed medical device companies and sales management, and senior management roles in the peripheral and neurovascular divisions of Boston Scientific. Ms. Rogers is a serial entrepreneur. She has over 20 patents in the medical device field, including ophthalmology, ENT, neurosurgery, cardiology, and nanotechnology. Ms. Rogers began her career at the Upjohn company. She serves as a Director of Silk Road Medical Inc since October 2012. She holds a BS in Zoology from San Diego State University.

CEO Compensation
  • Insufficient data for Erica to compare compensation growth.
  • Insufficient data for Erica to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Silk Road Medical management team in years:

4
Average Tenure
51
Average Age
  • The tenure for the Silk Road Medical management team is about average.
Management Team

Erica Rogers

TITLE
Chief Executive Officer
AGE
54
TENURE
6.6 yrs

Lucas Buchanan

TITLE
Chief Financial Officer
AGE
40
TENURE
2.8 yrs

Bob Nicholas

TITLE
Vice President of Operations & Engineering
AGE
55
TENURE
1.8 yrs

Andy Davis

TITLE
Executive Vice President of Global Sales & Marketing
AGE
49
TENURE
4 yrs

Alison Highlander

TITLE
Vice President of Human Resources

Sumaira MacDonald

TITLE
Executive Medical Director
TENURE
5.3 yrs

Ric Ruedy

TITLE
Executive Vice President of Clinical & Regulatory Affairs
AGE
51
Board of Directors Tenure

Average tenure and age of the Silk Road Medical board of directors in years:

2.8
Average Tenure
54
Average Age
  • The average tenure for the Silk Road Medical board of directors is less than 3 years, this suggests a new board.
Board of Directors

Erica Rogers

TITLE
Chief Executive Officer
AGE
54
TENURE
6.6 yrs

Jack Lasersohn

TITLE
Director
AGE
65
TENURE
12.1 yrs

Don Zurbay

TITLE
Director
AGE
50
TENURE
1.2 yrs

Tony Chou

TITLE
Director
AGE
57
TENURE
12.2 yrs

Bess Weatherman

TITLE
Director
AGE
58

Ruoxi Chen

TITLE
Director
AGE
34
TENURE
2.8 yrs

Robert Mittendorff

TITLE
Director
AGE
41
TENURE
1.8 yrs

Amr Kronfol

TITLE
Director
TENURE
0.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Silk Road Medical's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Silk Road Medical has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Silk Road Medical, Inc. operates as a medical device company in the United States. It offers ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent with clinical data regarding lasting safety outcomes; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices. The company was founded in 2007 and is headquartered in Sunnyvale, California.

Details
Name: Silk Road Medical, Inc
SILK
Exchange: NasdaqGM
Founded: 2007
$1,487,904,783
30,672,125
Website: http://silkroadmed.com
Address: Silk Road Medical, Inc
1213 Innsbruck Drive,
Sunnyvale,
California, 94089,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM SILK Common Stock Nasdaq Global Market US USD 04. Apr 2019
BST 2OW Common Stock Boerse-Stuttgart DE EUR 04. Apr 2019
Number of employees
Current staff
Staff numbers
176
Silk Road Medical employees.
Industry
Health Care Supplies
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/22 07:11
End of day share price update: 2019/05/21 00:00
Last estimates confirmation: 2019/05/09
Last earnings filing: 2019/05/15
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.